Welcome to our dedicated page for Adaptive Biotechnologies Corporation news (Ticker: ADPT), a resource for investors and traders seeking the latest updates and insights on Adaptive Biotechnologies Corporation stock.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) is a commercial-stage biotechnology company dedicated to leveraging the intricate biology of the adaptive immune system to innovate in the diagnosis and treatment of diseases. The company's proprietary immune medicine platform combines high-throughput sequencing with cutting-edge computational infrastructure to offer detailed analyses of T- and B-cell repertoires, critical elements in the body's immune response. Adaptive focuses on two primary business areas: Minimal Residual Disease (MRD) and Immune Medicine.
One of Adaptive's flagship products is clonoSEQ®, a highly sensitive and standardized test authorized by the FDA for detecting minimal residual disease (MRD) in patients with multiple myeloma (MM), B-cell acute lymphoblastic leukemia (B-ALL), and chronic lymphocytic leukemia (CLL). The clonoSEQ test is also available as a CLIA-validated laboratory developed test (LDT) for other lymphoid cancers, such as diffuse large B-cell lymphoma (DLBCL). The MRD status measured by clonoSEQ serves as a powerful predictor of patient outcomes, aiding in personalized treatment and monitoring strategies.
Adaptive Biotechnologies has formed strategic partnerships with leading biopharmaceutical companies. For instance, it collaborates with Genentech on T-cell receptor (TCR) based therapeutic products, providing a neoantigen-specific T-cell receptor identified using Adaptive's TCR discovery platform. The company also signed a multi-year collaboration with BeiGene to use clonoSEQ technology in developing novel therapies for lymphoid malignancies.
In terms of financial achievements, for the year ended December 31, 2023, Adaptive reported a total revenue of $170.3 million, with the MRD revenue contributing significantly to this growth. The company achieved substantial progress in clonoSEQ test volume and introduced strategic updates to maximize the value of its MRD and Immune Medicine businesses.
Adaptive Biotechnologies operates from biotech hubs in Seattle, Washington, and South San Francisco, California. Their team of world-class scientists and open, collaborative culture drive continuous innovation. The company's clinical diagnostics and pipeline developments aim to transform the clinical landscape, offering new hope for treating cancers, autoimmune disorders, and infectious diseases.
Recently, Adaptive Biotechnologies announced significant progress and strategic decisions to enhance its business operations. They integrated clonoSEQ into Epic’s specialty diagnostics suite, easing MRD monitoring accessibility for healthcare providers. The company continues to focus on driving operational efficiencies, as reflected by a decrease in operating expenses while maintaining sustainable growth.
Adaptive Biotechnologies remains committed to leveraging the adaptive immune system's potent capabilities to develop and commercialize immune-driven clinical products tailored to individual patient needs. With a robust cash position, Adaptive aims for profitability in its MRD business while making targeted investments in Immune Medicine.
Adaptive Biotechnologies (Nasdaq: ADPT) announced its participation in two upcoming investor conferences. The company will engage in a fireside chat at the William Blair 41st Annual Growth Stock Conference on June 1st at 6:40 a.m. PT and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8th at 12:50 p.m. PT. Interested parties can access the live and archived webcasts via the company’s website. Adaptive Biotechnologies focuses on translating the adaptive immune system's genetics into clinical products for disease diagnosis and treatment.
Adaptive Biotechnologies (ADPT) reported strong financial results for Q1 2021, with revenue of $38.4 million, marking an 84% year-over-year increase. The growth was driven by a 60% increase in sequencing revenue and a 103% increase in development revenue. However, operating expenses rose to $79.7 million, leading to a net loss of $40.6 million, compared to a loss of $31.4 million in Q1 2020. The company anticipates full-year 2021 revenue between $145 million and $155 million, indicating 52% growth at the midpoint.
Adaptive Biotechnologies (Nasdaq: ADPT) announced its participation in the BofA Securities 2021 Virtual Healthcare Conference. Management will engage in a fireside chat on May 11 at 8:45 a.m. PT. Interested parties can access the live and archived webcast on the company’s website. Adaptive Biotechnologies focuses on the adaptive immune system, developing diagnostic and therapeutic products for diseases like cancer and autoimmune conditions. The company has three commercial products and a strong clinical pipeline aimed at personalized medicine.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) plans to report its Q1 2021 financial results on May 5, 2021, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET, available via webcast. The company leverages the adaptive immune system for disease diagnostics and treatments, boasting three commercial products and a promising clinical pipeline targeting conditions like cancer and autoimmune diseases. The results announcement and the conference call are critical for investors seeking insights into company performance and future growth.
Adaptive Biotechnologies (Nasdaq: ADPT) announced FDA Emergency Use Authorization for its T-Detect COVID test, the first T cell-based diagnostic for detecting prior SARS-CoV-2 infections. The test demonstrated 97.1% sensitivity and 100% specificity. Developed in collaboration with Microsoft, T-Detect COVID allows individuals uncertain about past infections to confirm their status, marking a significant milestone in diagnostic testing. This technology leverages T cells' capabilities for improved disease detection and is expected to pave the way for future diagnostic tests across various diseases.
Adaptive Biotechnologies Corporation announced its participation in the Cowen 41st Annual Healthcare Conference, scheduled for March 2, 2021. The company will engage in a fireside chat at 7:30 a.m. PT / 10:30 a.m. ET.
Interested parties can access a live and archived webcast on their website. Adaptive focuses on utilizing the adaptive immune system to develop clinical products for diagnosing and treating diseases, with a strong emphasis on precision and individual patient care.
Adaptive Biotechnologies (Nasdaq: ADPT) announced its financial results for Q4 and the full year 2020, reporting revenues of $30.2 million for Q4 and $98.4 million for the year, marking increases of 25% and 16% respectively. The company launched T-Detect COVID, a T-cell based test for COVID-19, currently under FDA review for Emergency Use Authorization. Operating expenses rose 54% to $74.4 million in Q4, while net loss increased to $44.6 million. Despite these challenges, cash reserves stand strong at $806.8 million as of year-end.
Adaptive Biotechnologies (Nasdaq: ADPT) announced an expanded collaboration with Labcorp (NYSE: LH) to enhance patient access to its immune-driven clinical diagnostics. This includes commercial agreements for the clonoSEQ® and immunoSEQ® assays and a lab services agreement for the T-Detect COVID test. The collaboration builds on a prior agreement from May 2020, allowing blood collection for clonoSEQ and T-Detect at nearly 2,000 Labcorp patient service centers. Labcorp will promote clonoSEQ in hematology-oncology clinics and prepare to offer T-Detect COVID once it obtains Emergency Use Authorization from the FDA.
Adaptive Biotechnologies (Nasdaq: ADPT) has launched T-Detect COVID, a pioneering T-cell based test for confirming recent or past COVID-19 infections. This innovative test, currently under FDA review for Emergency Use Authorization, reportedly outperforms existing antibody tests. T-Detect is available for patients through nearly 2,000 Labcorp locations or via mobile phlebotomy services. The test leverages research from Microsoft’s TCR-Antigen Map to enhance early diagnosis of COVID-19 and potentially other diseases.
Adaptive Biotechnologies has announced a multi-year collaboration with AstraZeneca to extend its immunoSEQ T-MAP offering from COVID-19 into oncology.
This partnership enables Adaptive to utilize its database of over 58 billion immune cell receptors to provide T-cell receptor-antigen mapping data. This data may enhance treatment decisions and facilitate earlier disease detection.
AstraZeneca will provide biological samples, and Adaptive will receive quarterly payments along with additional fees, with future options for further collaboration.
FAQ
What is the current stock price of Adaptive Biotechnologies Corporation (ADPT)?
What is the market cap of Adaptive Biotechnologies Corporation (ADPT)?
What is Adaptive Biotechnologies Corporation known for?
What is clonoSEQ?
Who are some of Adaptive Biotechnologies' key partners?
What were Adaptive Biotechnologies' financial highlights for 2023?
How does Adaptive Biotechnologies contribute to personalized medicine?
What recent strategic decisions has Adaptive Biotechnologies made?
Where are Adaptive Biotechnologies' main operations located?
What is the company culture at Adaptive Biotechnologies?
What are some key clinical applications of clonoSEQ?
What are Adaptive Biotechnologies' future goals?
